Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.
Why Parabilis Medicines Stock Is On Investors’ Radar Parabilis Medicines (PBLS) has recently drawn fresh attention after a sharp single day move, with the stock closing at $27.26 and down around 10% ...
Hosted on MSN
How to play PBLS stock after the Parabilis IPO
Parabilis Medicines (PBLS) had a thunderous debut on Nasdaq this week — opening at a little over $33, up an exciting 67% versus the $20 initial public offering (IPO) price. PBLS raised some $670 ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Parabilis Medicines (PBLS) has filed for an upsized initial public offering in the U.S., seeking to raise more than $600M as the cancer drug developer backed by Regeneron (REGN) targets a valuation of ...
Parabilis Medicines, Inc. (PBLS) has filed to raise drug development funding via an IPO, according to an S-1 registration statement. The company is a clinical-stage biopharma developing helicon ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results